The big pharma has acquired a 15% equity stake in the privately-held gene therapy developer and an option to purchase all outstanding shares.

With the first generic versions of blockbuster brands like Advair, Lyrica, Restasis and Sensipar and the first biosimilars of Herceptin, Avastin and Rituxan expected to launch in the US, 2019 could be a notable year for generics and biosimilars.

Getting seven top pharma leaders in the same room, required to answer tough questions on drug pricing, is rare. Members of the Senate Finance Committee got that opportunity recently, but there are some questions our Pink Sheet reporters think they missed.

The company expects to complete a rolling NDA submission for its second RNAi therapeutic in mid-2019, and sees an opportunity to target severe and more moderate patients with acute hepatic porphyria.

Lilly will launch an authorized generic version of Humalog at a 50% discount to the brand to assist patients without insurance or a high deductible, who don't benefit from rebates.